RAS mutations and personalized cancer care: Targeting the future

touchEXPERT OPINIONS for touchONCOLOGY Listen to a medical oncologist, a pancreatic cancer specialist and a lung cancer specialist discuss the role of RAS mutations in solid tumours, notably pancreatic cancer and NSCLC, and how they may be therapeutically targeted to improve patient outcomes. The experts Dr David S Hong, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Dr Eileen M O’Reilly, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA Dr Rebecca S Heist, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA This touchPODCAST is for healthcare professionals outside of the UK.   This activity is funded by an independent medical education grant from Revolution Medicines.   This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.   For further information visit our website:  https://touchoncologyime.org/mutations-and-personalized-cancer-care-targeting-the-future/